edarbi
takeda pharma a/s - azilsartan medoxomil - hypertensjon - agenter som virker på renin-angiotensinsystemet - edarbi er indisert for behandling av essensiell hypertensjon hos voksne.
candesartan sandoz 16 mg
sandoz a/s - kandesartancileksetil - tablett - 16 mg
candesartan sandoz 4 mg
sandoz a/s - kandesartancileksetil - tablett - 4 mg
candesartan sandoz 8 mg
sandoz a/s - kandesartancileksetil - tablett - 8 mg
candesartan sandoz 32 mg
sandoz a/s - kandesartancileksetil - tablett - 32 mg
losartan/hydrochlorothiazide krka 100 mg / 12.5 mg
krka sverige ab - losartankalium / hydroklortiazid - tablett, filmdrasjert - 100 mg / 12.5 mg
valsartan/hydrochlorothiazide sandoz 80 mg / 12.5 mg
sandoz - københavn - valsartan / hydroklortiazid - tablett, filmdrasjert - 80 mg / 12.5 mg
valsartan/hydrochlorothiazide sandoz 160 mg / 12.5 mg
sandoz - københavn - valsartan / hydroklortiazid - tablett, filmdrasjert - 160 mg / 12.5 mg
valsartan/hydrochlorothiazide sandoz 160 mg / 25 mg
sandoz - københavn - valsartan / hydroklortiazid - tablett, filmdrasjert - 160 mg / 25 mg
qaialdo
nova laboratories ireland limited - spironolakton - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5. 1 og 5.